Search clinical trials for: Placebo (NNC0247-0829)

Total 53725 results

Novo Nordisk A/S

Completed

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Obesity

United States
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Obesity

Japan
Novo Nordisk A/S

Recruiting

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

Healthy Subjects

Germany
AbbVie (prior sponsor, Abbott)

Completed

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Osteoporosis
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Biocad

Completed

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (AURORA)

Seropositive RA

Russian Federation, Belarus
Abbott

Terminated

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Peptimmune

Completed

Safety Study of PI-0824 to Treat Pemphigus Vulgaris

Pemphigus Vulgaris

United States
University of Pennsylvania

Terminated

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Nicotine Addiction

United States
Merck Sharp & Dohme LLC

Completed

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Hepatic Insufficiency
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Renal Insufficiency
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump

Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Dry Eye With Sjögren's Syndrome

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

Overweight and Obesity

China
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Becker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular Dystrophy

United States
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Merck Sharp & Dohme LLC

Completed

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

Breast Cancer | Metastatic Bone Disease
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Healthy
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Gilead Sciences

Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Metastatic Castrate-Resistant Prostate Cancer

United States
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Dartmouth-Hitchcock Medical Center
Dartmouth College

Completed

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

Head and Neck Cancer

United States
National Center of Neurology and Psychiatry, Japan
Nippon Shinyaku Co., Ltd.

Completed

Exploratory Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy

Japan
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Extension Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy (DMD)

Japan
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany

3

Subscribe